|
Studies:
Pfizer’s New Anti-Cancer Drug Sutent Linked to High Blood
Pressure |
January
2, 2008--Separate studies
published in the New England
Journal of Medicine and The
Lancet link Pfizer’s new
anti-cancer drug Sutent (sunitinib) to high blood pressure in cancer
patients.
In the NEJM
study, researchers reported that Sutent can cause high blood
pressure in patients with kidney cancer. Last month, a study
published in The Lancet reported that Sutent increased blood pressure and the
risk of heart failure among patients with stomach cancer.
Sunitinib’s
cancer-fighting benefits may outweigh its cardiovascular risks, as
high blood pressure can often be managed. Authors of each study
agreed that patients taking sunitinib need to have their blood
pressure monitored. U.S.
News & World Report
|
